You just read:

New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis® (Carfilzomib)-Based Regimen

News provided by

Amgen

Jun 06, 2016, 16:00 ET